Russian Vaccine Shows Promise Against Mutated Ebola Strain

Dennis Logunov, director of the Gamaleya National Center for Epidemiology and Microbiology, announced the development of a new Russian vaccine that triggers an immune response and provides protection against the Bundibugyo strain responsible for Ebola outbreaks in Africa.

Logunov highlighted that the center has created prototype vaccines demonstrating the ability to stimulate immunity and preventive efficacy in alternative tests using simplified viral variants. He noted that these variants closely match the original virus and represent an initial step toward validating the vaccine's effectiveness.

He emphasized that further progress depends on a fundamental decision regarding the necessity of the vaccine and acquiring a sample of the pathogen currently circulating in Africa. Logunov confirmed the center's readiness to conduct research if Africa shows genuine interest and willingness to supply the required information.

Meanwhile, Andrey Brodious, chief pediatric allergist and immunologist at the Moscow Region Ministry of Health, explained the method for proving the new vaccine's efficacy against a challenging-to-access infection. This involves creating an artificial model using a laboratory-produced substitute virus.